Porton Advanced
Cranbury, NJ (US HQ); GMP manufacturing sites in Suzhou, China
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (8)
○ EMA GMP
○ MHRA GMP
Quick Facts: Porton Advanced
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Cranbury, NJ (US HQ); GMP manufacturing sites in Suzhou, China
- Modalities
- Lentiviral Vector, AAV, Adenoviral Vector, Plasmid DNA, CAR-T, TCR-T, CAR-NK, HSC, Exosome, mRNA
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Porton Advanced
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesLentiviral Vector, AAV, Adenoviral Vector, Plasmid DNA, CAR-T, TCR-T, CAR-NK, HSC, Exosome, mRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (10 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press8 articles
Broad modality coverage (10 modalities)
Recent News 8 articles
Porton Advanced and Geneseed Biotech focus on advancing circRNA innovative therapeutics in China - BioSpectrum Asia
Porton Advanced Solutions and EVA Pharma Sign MoU to Collaborate on CAR T-Cell Therapy Development - geneonline.com
Dark Horse Consulting Group and Porton Advanced Announce - GlobeNewswire
Porton Advanced Solutions completes a Series B financing round to expand its end-to-end Gene and Cell Therapy CDMO Platforms - PR Newswire
Porton Advanced and Kun Tuo Announce Strategic Partnership to Deepen Gene and Cell Therapy CDMO and Clinical Research Services - PR Newswire
Porton Advanced and IQVIA backed Kun Tuo team to grow in China CGT market - BioXconomy
Porton Advanced and EVA Pharma Partner to Boost CAR T-Cell Therapy Manufacturing in the Middle East and Africa - BioPharma APAC
Porton and DanausGT look to boost development of gene and cell therapy - Labiotech.eu
Frequently Asked Questions About Porton Advanced
What is Porton Advanced's CDMO Signal Score?
Porton Advanced has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Porton Advanced for a manufacturing program?
Use the free AI matchmaker to compare Porton Advanced against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
CoJourney Inc.
Ambler, PA (US operations; primary manufacturing in Hangzhou, Zhejiang, China)
Plasmid DNA, AAV, Adenoviral, Lentiviral, Retroviral, mRNA, sgRNA, Exosome
Catalent
Bagsværd, Denmark (operating under Novo Holdings)
Signal Score: 76.5
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
Signal Score: 75.1
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
Rose BioSolutions
Rockville, MD
Plasmid DNA, AAV, Lentiviral, Adenoviral, CAR-T, Cell Therapy, Gene Editing, Cell Solutions / Starting Materials
Made Scientific
Newark, NJ
Signal Score: 61.5
CAR-T, Cell Therapy, AAV